ClinicalTrials.gg
CompletedNCT05964335CORALUpdated Jun 26, 2026Results posted

Cough Reduction in IPF With Nalbuphine ER

A Phase 2 interventional study of NAL ER and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Trevi Therapeutics. Completed at 59 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Trevi Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 22 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.

Enrollment
28th of 83
165 · median 109
Started
2024
with 8 others
Phase 2
43 of 103
9 open now
Registered
77th of 103
by date
Lead sponsor
3 of 103
Trevi Therapeutics

Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 28th largest by enrollment of the 83 interventional ones that give a count, is one of 9 that started in 2024, is one of 43 in phase 2, and was the 77th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Cough
  • Nalbuphine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of IPF as determined by the Principal Investigator based on ATS/ERS/JRS/ALAT guidelines.
  • Cough Severity Score ≥ 4 on CS-NRS (Cough Severity Numerical Rating Scale) during the Screening period and Baseline.
  • History of chronic cough for at least 8 weeks before screening.
  • SpO2 ≥ 92%, taken after at least 5 minutes in a sitting position, undisturbed and non-stimulated (Saturation of with Oxygen as Measured by Pulse Oximetry).
  • FVC ≥ 40% predicted of normal - Forced Vital Capacity, as determined by spirometry adhering to ATS/ERS guidelines.
  • DLCO ≥ 25% predicted of normal - Diffusing capacity of the lung for carbon monoxide corrected for hemoglobin, assessed within the last 12 weeks, or at the time of screening.

Exclusion criteria

Exclusion Criteria:

  • Currently on continuous oxygen therapy for longer than 16 hours at any level or delivered by any modality. Intermittent oxygen use of any duration over any given 24-hour period is allowed.
  • Inadequate swallow reflex as assessed by the ability to sip 3 fluid oz (or 89 mL) of water without coughing or choking.
  • Upper or lower respiratory tract infection in the last 8 weeks prior to the baseline visit.
  • Clinical history of aspiration pneumonitis.
  • Diagnosis of sleep apnea.
  • Abnormal kidney or liver functions based on Screening lab results.
  • Known to nalbuphine or to NAL ER
  • History of major psychiatric disorder.
  • History of substance abuse.
  • Significant medical condition or other factors that may interfere with the participant's ability to successfully complete the study.
  • Pregnant or lactating female participant.
  • Known intolerance (gastrointestinal, central nervous system symptoms), hypersensitivity, drug allergy following the use of an opioid drug.
  • Use of opiates is prohibited within 14 days prior to the baseline visit.
  • Use of benzodiazepines are prohibited within 14 days prior to the baseline visit and for the duration of the study.
  • Monoamine oxidase inhibitors (MAOIs) including methylene blue (methylthioninium chloride) and the antibiotic linezolid are prohibited within 14 days prior to the baseline visit and for the duration of the study.
  • Use of oral cough treatment is prohibited within 4 weeks prior to the baseline visit and for the duration of the study.
  • Exposure to any medication, including placebo, is prohibited within 4 weeks prior to the baseline visit and for the duration of the study.
  • Medications prescribed as cough suppressants are prohibited unless on a stable dose 14-days prior to the baseline visit and are expected to remain on that dose for the duration of the study.
  • Use of medications that affect serotonergic neurotransmission and that when used concomitantly with opioids can increase the risk of serotonin syndrome are prohibited unless on a stable dose 14-days prior to the baseline visit and are expected to remain on that dose for the duration of the study.
  • Anti-fibrotic medications are prohibited unless on a stable dose for 8 weeks prior to the baseline visit and are expected to remain on that dose for the duration of the study.
  • Strong inhibitors/inducers of the P450 Isozymes are prohibited unless on a stable dose for 14-days prior to baseline visit and are expected to remain on that dose for the duration of the study.
  • Use of a medication having a "known risk" of Torsade de Pointes (categorized as "KR" on the Credible Meds® website.) 4 weeks prior to Baseline.
  • Use of unstable doses of medications associated with a potential risk of but not clearly associated with Torsade de Pointes within 4 weeks of screening.

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    NAL ER 27 mg

    Participants were titrated over 2 weeks to NAL ER 27 mg BID, then maintained at the fixed dose for 4 weeks (total 6 weeks of treatment).

    Drug: NAL ER

  • Experimental
    NAL ER 54 mg

    Participants were titrated over 2 weeks to NAL ER 54 mg BID, then maintained at the fixed dose for 4 weeks (total 6 weeks of treatment).

    Drug: NAL ER

  • Experimental
    NAL ER 108 mg

    Participants were titrated over 2 weeks to NAL ER 108 mg BID, then maintained at the fixed dose for 4 weeks (total 6 weeks of treatment).

    Drug: NAL ER

  • Placebo comparator
    Placebo

    Participants received a matching placebo BID, using the same 2-week blinded titration schedule and 4-week fixed-dose period as the active treatment arms (6 weeks total).

    Drug: Placebo

Interventions

  • DrugNAL ER

    Oral tablets

    Also known as: Nalbuphine

  • DrugPlacebo

    Oral tablets

  • DrugNAL ER

    Oral Tablets

    Also known as: Nalbuphine

  • DrugNAL ER

    Oral tablets

    Also known as: Nalbuphine

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in 24-hour Cough Frequency at Week 6

    Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Relative Change From Baseline in Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E-RS:IPF) Cough Subscale at Week 6

    The E-RS:IPF is a respiratory symptom subscale of the exacerbation of chronic pulmonary disease tool (EXACT) and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?). The possible score range is 0 (not at all) to 4 (almost constantly). Higher scores indicate more severe symptoms. The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  2. Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: Up to Week 12

  3. Relative Change From Baseline in 24-hour Cough Frequency at Week 6

    Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Weeks 6

  4. Percentage of Responders With ≥30%, ≥50% and ≥75% Reduction in the 24-Hour Cough Frequency at Week 6

    Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Week 6. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  5. Relative Change From Baseline in Awake Cough Frequency at Week 6

    Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  6. Relative Change From Baseline in Sleep Cough Frequency at Week 6

    Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  7. Relative Change From Baseline in E-RS: IPF Cough Subscale at Week 6

    The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?) with a score range of 0 (not at all) to 4 (almost constantly). The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  8. Percentage of E-RS: IPF Cough Subscale Responders With At Least One Category Improvement at Week 6

    The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2) with a score range of 0 (not at all) to 4 (almost constantly). Responders are defined as those with at least one category reduction (improvement) by ≥1 point at Week 6. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  9. Change From Baseline in E-RS:IPF Total Score at Week 6

    The Total E-RS:IPF includes all 11 items from the scale and was developed for use in IPF. Items assignments to domains of the E-RS:IPF are as follows: the RS-Breathlessness domain (Items 7-11) has a score range of 0-23; the IPF-Chest domain (Items 1, 5, and 6) has a score range of 0-12; the IPF-Cough domain (Item 2) has a score range of 0-4; the IPF-Sputum domain (Items 3 and 4) has a score range of 0-8; and the E-RS:IPF total score (Items 1-11) ranges from 0-47. For each day, the sum of the item-level raw scores forms the E-RS:IPF total score. Higher scores indicate more severe symptoms. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  10. Change From Baseline in IPF-Breathlessness Subdomain Score at Week 6

    The E-RS:IPF consists of a subset of 11 items from the EXACT and was developed for use in IPF. The Breathlessness subdomain score includes 5 items (Item 7: Were you breathless today, Item 8: Describe how breathless you were today, Item 9: Were you short of breath today when performing your usual personal care activities like washing or dressing, Item 10: Were you short of breath today when performing your usual indoor activities like cleaning or household work, Item 11: Were you short of breath today when performing your usual activities outside the home such as yard work or errands), all of which required the participant to report the effect of activities on shortness of breath. The possible score range is 0 to 23. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study. A higher score indicates more severe symptoms.

    Time frame: Baseline, Week 6

  11. Change From Baseline in IPF-Cough Subdomain Score at Week 6

    The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subdomain score includes single item (item 2: How often did you cough today?) The possible score range is 0 (not at all) to 4 (almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  12. Change From Baseline in IPF-Sputum Subdomain Score at Week 6

    The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Sputum subdomain score includes 2 items (Item 3: How much mucus (phlegm) did you bring up when coughing today? and Item 4: How difficult was it to bring up mucus (phlegm) today?), which ask about quantity and difficulty in bringing up phlegm. The possible score range is 0-8. Higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  13. Change From Baseline in IPF-Chest Subdomain Score at Week 6

    The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Chest subdomain score includes 3 items (Item 1: (Did your chest feel congested today?), Item 5: (Did you have chest discomfort today?), and Item 6: (Did your chest feel tight today?)). These questions solicited information on chest congestion, discomfort, and tightness. The possible score range is 0-12. A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  14. Change From Baseline in Cough Severity Numerical Rating Scale (CS-NRS) at Week 6

    The CS-NRS is a single item scale in which participants described the severity of their cough in the past 24 hours on a scale of 0 (no cough) to 10 (worst possible cough). A negative change from Baseline indicates improvement. A higher score indicates more severe symptoms. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  15. Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 6

    LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  16. Percentage of LCQ Total Score Responders With 1.3-Point Increase Response at Week 6

    LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. Percentage of LCQ Total Score responders are presented in this outcome measure. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  17. Change From Baseline in LCQ Domains at Week 6

    LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and each domain score ranges from 1 to 7. Higher scores indicate better physical, psychological, and social status respectively. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  18. Change From Baseline in Living With Pulmonary Fibrosis Impacts Questionnaire (L-IPF©) Impacts Raw Sum Score at Week 6

    The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The Impacts module yields a single Impacts score that is presented in this outcome measure. Each item's score ranges from 0-3. The score range for the L-IPF overall impacts raw sum score is 0-60, with higher scores indicating severe adverse impact. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  19. Change From Baseline in L-IPF Symptoms Domain Scores at Week 6

    The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The L-IPF Symptoms module measures the various symptoms associated with IPF. The module contains 15 items that fall into 3 domains: Dyspnea, Cough, and Energy. Each item consists of a 0-3 score range. Dyspnea consists of 7 items and has a raw sum score range of 0-21 with higher scores indicating worsening dyspnea symptoms, Cough consists of 5 items and has a raw sum score range of 0-15 with higher scores indicating worsening cough symptoms, and Energy consists of 3 items and has a raw sum score range of 0-9 with higher scores indicating worsening energy. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  20. Number of Participants With Shift From Baseline in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L™) at Week 6

    The EQ-5D-5L is a participant reported outcome and comprises of a descriptive system with 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The recall period was the day that the questions were being completed. Each of the 5 dimensions in the descriptive system had 5 levels: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems. Higher scores indicate worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  21. Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score at Week 6

    The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  22. Patient Global Impression of Change (PGI-C) Cough Score at Week 6

    The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.

    Time frame: At Week 6

  23. Percentage of Participants With Improvement by ≥1 and ≥ 2 on PGI-C Cough

    The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  24. Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-C Cough

    The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  25. Percentage of Participants With no Change on PGI-C Cough

    The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3=much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  26. Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-S Cough

    The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  27. Percentage of Participants With Worsening by ≥1 and ≥2 and PGI-S Cough

    The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  28. Percentage of Participants With no Change on PGI-S Cough

    The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  29. Change From Baseline in PGI-S IPF at Week 6

    PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  30. PGI-C IPF Score at Week 6

    The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.

    Time frame: At Week 6

  31. Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-C IPF

    The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  32. Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-C IPF

    The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  33. Percentage of Participants With no Change on PGI-C IPF

    The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  34. Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-S-IPF

    PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  35. Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-S-IPF

    PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  36. Percentage of Participants With no Change on PGI-S-IPF

    PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  37. Change From Baseline in Clinicians Global Impression of Severity (CGI-S) Score at Week 6

    The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range of 0-3. (0 = no cough, 1 = mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

    Time frame: Baseline, Week 6

  38. CGI-C IPF Score at Week 6

    The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough.

    Time frame: At Week 6

  39. Percentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Change (CGI-C) at Week 6

    The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  40. Percentage of Participants With Worsening by ≥1 and ≥2 on the CGI-C at Week 6

    The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  41. Percentage of Participants With no Change on the CGI-C at Week 6

    The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  42. Percentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Severity (CGI-S) at Week 6

    The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  43. Percentage of Participants With Worsening by ≥1 and ≥2 on the CGI-S at Week 6

    The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

  44. Percentage of Participants With no Change on the CGI-S at Week 6

    The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

    Time frame: At Week 6

07

Results

Posted Jun 26, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Started40424340
Completed37403537
Not completed3283
Withdrew: Discontinued treatment and chose not to start follow-up0233
Withdrew: Discontinued treatment and completed follow-up3050

Outcome measures

PrimaryRelative Change From Baseline in 24-hour Cough Frequency at Week 6

Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · percent change
Relative Change From Baseline in 24-hour Cough Frequency at Week 6
percent changePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Relative Change From Baseline in 24-hour Cough Frequency at Week 6-0.19 ± 0.173-0.90 ± 0.168-1.27 ± 0.176-1.32 ± 0.174
Statistical analysis
  • Placebo vs NAL ER 27 mg · MMRM · p = 0.0028 (Mixed model repeated measures (MMRM): Treatment group, visit and visit by treatment group interaction as a fixed effect; log-transformed baseline 24-hour cough frequency, sex and antifibrotic treatment as covariates.) · Least square (ls) mean difference: -0.71 · 95% CI -1.17 to -0.25
  • Placebo vs NAL ER 54 mg · MMRM · p = 0.0000 (MMRM: Treatment group, visit and visit by treatment group interaction as a fixed effect; log-transformed baseline 24-hour cough frequency, sex and antifibrotic treatment as covariates.) · Least square (ls) mean difference: -1.08 · 95% CI -1.55 to -0.61
  • Placebo vs NAL ER 108 mg · MMRM · p = 0.0000 (MMRM: Treatment group, visit and visit by treatment group interaction as a fixed effect; log-transformed baseline 24-hour cough frequency, sex and antifibrotic treatment as covariates.) · Least square (ls) mean difference: -1.14 · 95% CI -1.61 to -0.67
SecondaryRelative Change From Baseline in Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E-RS:IPF) Cough Subscale at Week 6

The E-RS:IPF is a respiratory symptom subscale of the exacerbation of chronic pulmonary disease tool (EXACT) and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?). The possible score range is 0 (not at all) to 4 (almost constantly). Higher scores indicate more severe symptoms. The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · percent change
Relative Change From Baseline in Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E-RS:IPF) Cough Subscale at Week 6
percent changePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Relative Change From Baseline in Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E-RS:IPF) Cough Subscale at Week 6-23.01 ± 27.515-31.57 ± 29.663-43.07 ± 25.477-42.35 ± 30.151
SecondaryNumber of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)25303433
SecondaryRelative Change From Baseline in 24-hour Cough Frequency at Week 6

Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Weeks 6
Reported as:
Least squares mean · percent change
Relative Change From Baseline in 24-hour Cough Frequency at Week 6
percent changePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Relative Change From Baseline in 24-hour Cough Frequency at Week 6-0.19 (-0.53 to 0.16)-0.90 (-1.23 to -0.57)-1.27 (-1.61 to -0.92)-1.32 (-1.67 to -0.98)
SecondaryPercentage of Responders With ≥30%, ≥50% and ≥75% Reduction in the 24-Hour Cough Frequency at Week 6

Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Week 6. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Responders With ≥30%, ≥50% and ≥75% Reduction in the 24-Hour Cough Frequency at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
>=30% Reduction at Week 645.975.077.181.1
>=50% Reduction at Week 618.960.062.964.9
>=75% Reduction at Week 65.417.537.143.2
SecondaryRelative Change From Baseline in Awake Cough Frequency at Week 6

Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · percent change
Relative Change From Baseline in Awake Cough Frequency at Week 6
percent changePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Relative Change From Baseline in Awake Cough Frequency at Week 663.267 ± 467.6832-44.855 ± 38.6632-51.007 ± 51.3002-56.692 ± 40.7140
SecondaryRelative Change From Baseline in Sleep Cough Frequency at Week 6

Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · percent change
Relative Change From Baseline in Sleep Cough Frequency at Week 6
percent changePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Relative Change From Baseline in Sleep Cough Frequency at Week 613747.619 ± 77416.947429.996 ± 309.716615.673 ± 222.5858-46.104 ± 85.6358
SecondaryRelative Change From Baseline in E-RS: IPF Cough Subscale at Week 6

The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?) with a score range of 0 (not at all) to 4 (almost constantly). The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · percent change
Relative Change From Baseline in E-RS: IPF Cough Subscale at Week 6
percent changePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Relative Change From Baseline in E-RS: IPF Cough Subscale at Week 6-23.01 ± 27.515-31.57 ± 29.663-43.07 ± 25.477-42.35 ± 30.151
SecondaryPercentage of E-RS: IPF Cough Subscale Responders With At Least One Category Improvement at Week 6

The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2) with a score range of 0 (not at all) to 4 (almost constantly). Responders are defined as those with at least one category reduction (improvement) by ≥1 point at Week 6. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of E-RS: IPF Cough Subscale Responders With At Least One Category Improvement at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of E-RS: IPF Cough Subscale Responders With At Least One Category Improvement at Week 636.835.061.156.8
SecondaryChange From Baseline in E-RS:IPF Total Score at Week 6

The Total E-RS:IPF includes all 11 items from the scale and was developed for use in IPF. Items assignments to domains of the E-RS:IPF are as follows: the RS-Breathlessness domain (Items 7-11) has a score range of 0-23; the IPF-Chest domain (Items 1, 5, and 6) has a score range of 0-12; the IPF-Cough domain (Item 2) has a score range of 0-4; the IPF-Sputum domain (Items 3 and 4) has a score range of 0-8; and the E-RS:IPF total score (Items 1-11) ranges from 0-47. For each day, the sum of the item-level raw scores forms the E-RS:IPF total score. Higher scores indicate more severe symptoms. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in E-RS:IPF Total Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in E-RS:IPF Total Score at Week 6-3.36 ± 4.967-4.17 ± 5.280-7.15 ± 5.784-5.41 ± 5.561
SecondaryChange From Baseline in IPF-Breathlessness Subdomain Score at Week 6

The E-RS:IPF consists of a subset of 11 items from the EXACT and was developed for use in IPF. The Breathlessness subdomain score includes 5 items (Item 7: Were you breathless today, Item 8: Describe how breathless you were today, Item 9: Were you short of breath today when performing your usual personal care activities like washing or dressing, Item 10: Were you short of breath today when performing your usual indoor activities like cleaning or household work, Item 11: Were you short of breath today when performing your usual activities outside the home such as yard work or errands), all of which required the participant to report the effect of activities on shortness of breath. The possible score range is 0 to 23. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study. A higher score indicates more severe symptoms.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in IPF-Breathlessness Subdomain Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in IPF-Breathlessness Subdomain Score at Week 6-0.92 ± 2.686-1.63 ± 2.733-2.65 ± 3.020-1.94 ± 3.062
SecondaryChange From Baseline in IPF-Cough Subdomain Score at Week 6

The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subdomain score includes single item (item 2: How often did you cough today?) The possible score range is 0 (not at all) to 4 (almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in IPF-Cough Subdomain Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in IPF-Cough Subdomain Score at Week 6-0.66 ± 0.756-0.76 ± 0.648-1.19 ± 0.762-1.03 ± 0.726
SecondaryChange From Baseline in IPF-Sputum Subdomain Score at Week 6

The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Sputum subdomain score includes 2 items (Item 3: How much mucus (phlegm) did you bring up when coughing today? and Item 4: How difficult was it to bring up mucus (phlegm) today?), which ask about quantity and difficulty in bringing up phlegm. The possible score range is 0-8. Higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in IPF-Sputum Subdomain Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in IPF-Sputum Subdomain Score at Week 6-0.69 ± 1.056-0.80 ± 1.125-1.53 ± 1.280-1.04 ± 1.150
SecondaryChange From Baseline in IPF-Chest Subdomain Score at Week 6

The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Chest subdomain score includes 3 items (Item 1: (Did your chest feel congested today?), Item 5: (Did you have chest discomfort today?), and Item 6: (Did your chest feel tight today?)). These questions solicited information on chest congestion, discomfort, and tightness. The possible score range is 0-12. A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in IPF-Chest Subdomain Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in IPF-Chest Subdomain Score at Week 6-1.08 ± 1.544-0.97 ± 1.605-1.78 ± 1.644-1.41 ± 1.609
SecondaryChange From Baseline in Cough Severity Numerical Rating Scale (CS-NRS) at Week 6

The CS-NRS is a single item scale in which participants described the severity of their cough in the past 24 hours on a scale of 0 (no cough) to 10 (worst possible cough). A negative change from Baseline indicates improvement. A higher score indicates more severe symptoms. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in Cough Severity Numerical Rating Scale (CS-NRS) at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in Cough Severity Numerical Rating Scale (CS-NRS) at Week 6-1.50 ± 2.016-2.03 ± 1.991-3.17 ± 2.260-3.00 ± 2.053
SecondaryChange From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 6

LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 60.510 ± 4.35882.137 ± 3.16603.724 ± 4.04993.367 ± 3.3014
SecondaryPercentage of LCQ Total Score Responders With 1.3-Point Increase Response at Week 6

LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. Percentage of LCQ Total Score responders are presented in this outcome measure. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of LCQ Total Score Responders With 1.3-Point Increase Response at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of LCQ Total Score Responders With 1.3-Point Increase Response at Week 635.753.675.080.8
SecondaryChange From Baseline in LCQ Domains at Week 6

LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and each domain score ranges from 1 to 7. Higher scores indicate better physical, psychological, and social status respectively. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in LCQ Domains at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Physical Assessment Score0.319 ± 1.13480.718 ± 1.17501.085 ± 1.20190.918 ± 1.1319
Psychological Assessment Score0.042 ± 1.62970.651 ± 1.13761.255 ± 1.67471.286 ± 1.2155
Social Assessment Score0.148 ± 1.84270.769 ± 1.15391.384 ± 1.46011.163 ± 1.1789
SecondaryChange From Baseline in Living With Pulmonary Fibrosis Impacts Questionnaire (L-IPF©) Impacts Raw Sum Score at Week 6

The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The Impacts module yields a single Impacts score that is presented in this outcome measure. Each item's score ranges from 0-3. The score range for the L-IPF overall impacts raw sum score is 0-60, with higher scores indicating severe adverse impact. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in Living With Pulmonary Fibrosis Impacts Questionnaire (L-IPF©) Impacts Raw Sum Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in Living With Pulmonary Fibrosis Impacts Questionnaire (L-IPF©) Impacts Raw Sum Score at Week 60.3 ± 8.80-6.0 ± 10.99-4.2 ± 10.91-5.6 ± 11.72
SecondaryChange From Baseline in L-IPF Symptoms Domain Scores at Week 6

The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The L-IPF Symptoms module measures the various symptoms associated with IPF. The module contains 15 items that fall into 3 domains: Dyspnea, Cough, and Energy. Each item consists of a 0-3 score range. Dyspnea consists of 7 items and has a raw sum score range of 0-21 with higher scores indicating worsening dyspnea symptoms, Cough consists of 5 items and has a raw sum score range of 0-15 with higher scores indicating worsening cough symptoms, and Energy consists of 3 items and has a raw sum score range of 0-9 with higher scores indicating worsening energy. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in L-IPF Symptoms Domain Scores at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Dyspnea Domain Raw Sum Score-0.2 ± 4.84-2.0 ± 5.64-3.0 ± 5.28-2.2 ± 5.68
Cough Domain Raw Sum Score-1.4 ± 3.90-2.9 ± 4.60-3.9 ± 3.89-4.0 ± 4.59
Energy Domain Raw Sum Score-0.7 ± 2.390.2 ± 3.03-0.8 ± 2.18-0.2 ± 2.49
SecondaryNumber of Participants With Shift From Baseline in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L™) at Week 6

The EQ-5D-5L is a participant reported outcome and comprises of a descriptive system with 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The recall period was the day that the questions were being completed. Each of the 5 dimensions in the descriptive system had 5 levels: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems. Higher scores indicate worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L™) at Week 6
ParticipantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Mobility: No Problems101499
Mobility: Slight Problems74106
Mobility: Moderate Problems9578
Mobility: Severe Problems1311
Mobility: Extreme Problems0000
Self-Care: No Problems12161713
Self-Care: Slight Problems6468
Self-Care: Moderate Problems9422
Self-Care: Severe Problems0221
Self-Care: Extreme Problems0000
Usual Activities: No Problems610710
Usual Activities: Slight Problems119117
Usual Activities: Moderate Problems9465
Usual Activities: Severe Problems1222
Usual Activities: Extreme Problems0110
Pain/Discomfort: No Problems8111013
Pain/Discomfort: Slight Problems119107
Pain/Discomfort: Moderate Problems6664
Pain/Discomfort: Severe Problems2010
Pain/Discomfort: Extreme Problems0000
Anxiety/Depression: No Problems1113910
Anxiety/Depression: Slight Problems78109
Anxiety/Depression: Moderate Problems8565
Anxiety/Depression: Severe Problems1020
Anxiety/Depression: Extreme Problems0000
SecondaryChange From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score at Week 6

The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score at Week 6-0.3 ± 0.85-0.9 ± 0.89-1.0 ± 0.71-0.9 ± 0.80
SecondaryPatient Global Impression of Change (PGI-C) Cough Score at Week 6

The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.

Time frame:
At Week 6
Reported as:
Mean · score on a scale
Patient Global Impression of Change (PGI-C) Cough Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Patient Global Impression of Change (PGI-C) Cough Score at Week 6-1.2 ± 1.07-1.6 ± 1.34-1.9 ± 1.38-2.2 ± 0.87
SecondaryPercentage of Participants With Improvement by ≥1 and ≥ 2 on PGI-C Cough

The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement by ≥1 and ≥ 2 on PGI-C Cough
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Improvement by ≥1 at Week 668.081.574.1100
Improvement by ≥2 at Week 632.055.663.070.8
SecondaryPercentage of Participants With Worsening by ≥1 and ≥2 on PGI-C Cough

The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-C Cough
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Worsening by ≥1 at Week 6011.13.70
Worsening by ≥2 at Week 60000
SecondaryPercentage of Participants With no Change on PGI-C Cough

The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3=much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With no Change on PGI-C Cough
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of Participants With no Change on PGI-C Cough32.07.422.20
SecondaryPercentage of Participants With Improvement by ≥1 and ≥2 on PGI-S Cough

The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-S Cough
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Improvement by ≥ 1: Week 640.074.174.170.8
Improvement by ≥ 2: Week 68.018.522.220.8
SecondaryPercentage of Participants With Worsening by ≥1 and ≥2 and PGI-S Cough

The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening by ≥1 and ≥2 and PGI-S Cough
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Worsening by ≥1; Week 616.07.404.2
Worsening by ≥2; Week 60000
SecondaryPercentage of Participants With no Change on PGI-S Cough

The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With no Change on PGI-S Cough
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of Participants With no Change on PGI-S Cough44.018.525.925.0
SecondaryChange From Baseline in PGI-S IPF at Week 6

PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in PGI-S IPF at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in PGI-S IPF at Week 6-0.3 ± 0.84-0.2 ± 0.75-0.6 ± 0.93-0.4 ± 0.82
SecondaryPGI-C IPF Score at Week 6

The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.

Time frame:
At Week 6
Reported as:
Mean · score on a scale
PGI-C IPF Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
PGI-C IPF Score at Week 6-0.8 ± 0.82-1.0 ± 1.06-1.1 ± 1.17-1.2 ± 1.47
SecondaryPercentage of Participants With Improvement by ≥1 and ≥2 on PGI-C IPF

The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-C IPF
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Improvement by ≥1; Week 660.063.059.366.7
Improvement by ≥2; Week 616.037.037.050.0
SecondaryPercentage of Participants With Worsening by ≥1 and ≥2 on PGI-C IPF

The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-C IPF
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Worsening by ≥1; Week 607.408.3
Worsening by ≥2; Week 60008.3
SecondaryPercentage of Participants With no Change on PGI-C IPF

The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With no Change on PGI-C IPF
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of Participants With no Change on PGI-C IPF40.029.640.725.0
SecondaryPercentage of Participants With Improvement by ≥1 and ≥2 on PGI-S-IPF

PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-S-IPF
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Improvement by ≥1; Week 648.033.348.141.7
Improvement by ≥2; Week 603.718.58.3
SecondaryPercentage of Participants With Worsening by ≥1 and ≥2 on PGI-S-IPF

PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-S-IPF
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Worsening by ≥1; Week 616.014.811.112.5
Worsening by ≥2; Week 64.0000
SecondaryPercentage of Participants With no Change on PGI-S-IPF

PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With no Change on PGI-S-IPF
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of Participants With no Change on PGI-S-IPF36.051.940.745.8
SecondaryChange From Baseline in Clinicians Global Impression of Severity (CGI-S) Score at Week 6

The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range of 0-3. (0 = no cough, 1 = mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.

Time frame:
Baseline, Week 6
Reported as:
Mean · score on a scale
Change From Baseline in Clinicians Global Impression of Severity (CGI-S) Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Change From Baseline in Clinicians Global Impression of Severity (CGI-S) Score at Week 6-1.0 ± NA-1.5 ± 0.71-1.4 ± 0.52-0.4 ± 0.55
SecondaryCGI-C IPF Score at Week 6

The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough.

Time frame:
At Week 6
Reported as:
Mean · score on a scale
CGI-C IPF Score at Week 6
score on a scalePlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
CGI-C IPF Score at Week 62.0 ± NA3.0 ± 1.411.9 ± 0.641.8 ± 0.45
SecondaryPercentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Change (CGI-C) at Week 6

The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Change (CGI-C) at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Improvement by ≥1; Week 610050100100
Improvement by ≥2; Week 610050.087.5100
SecondaryPercentage of Participants With Worsening by ≥1 and ≥2 on the CGI-C at Week 6

The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening by ≥1 and ≥2 on the CGI-C at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Worsening by ≥1; Week 60000
Worsening by ≥2; Week 60000
SecondaryPercentage of Participants With no Change on the CGI-C at Week 6

The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With no Change on the CGI-C at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of Participants With no Change on the CGI-C at Week 60000
SecondaryPercentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Severity (CGI-S) at Week 6

The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Severity (CGI-S) at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Improvement by ≥1; Week 610010010040.0
Improvement by ≥2; Week 6050.037.50
SecondaryPercentage of Participants With Worsening by ≥1 and ≥2 on the CGI-S at Week 6

The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Worsening by ≥1 and ≥2 on the CGI-S at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Worsening by ≥1; Week 60000
Worsening by ≥2; Week 60000
SecondaryPercentage of Participants With no Change on the CGI-S at Week 6

The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.

Time frame:
At Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With no Change on the CGI-S at Week 6
percentage of participantsPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
Percentage of Participants With no Change on the CGI-S at Week 600060.0

Adverse events

Collected over Up to Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/40 (0%)4/40 (10%)23/40 (57.5%)
NAL ER 27 mg0/42 (0%)1/42 (2.4%)30/42 (71.4%)
NAL ER 54 mg0/43 (0%)0/43 (0%)34/43 (79.1%)
NAL ER 108 mg0/40 (0%)1/40 (2.5%)33/40 (82.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
FatigueGeneral disorders0/400/420/431/40
Upper respiratory tract infectionInfections and infestations1/400/420/430/40
SomnolenceNervous system disorders0/400/420/431/40
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/400/420/430/40
Respiratory symptomRespiratory, thoracic and mediastinal disorders1/400/420/430/40
Hepatic enzyme increasedInvestigations1/400/420/430/40
HyperglycaemiaMetabolism and nutrition disorders1/400/420/430/40
Pneumonia influenzalInfections and infestations0/401/420/430/40
Pneumonia pseudomonalInfections and infestations0/401/420/430/40
Respiratory failureRespiratory, thoracic and mediastinal disorders0/401/420/430/40
Most frequent other events
Showing 10 of 138
Most frequent other events
EventPlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mg
NauseaGastrointestinal disorders2/406/4216/4320/40
DizzinessNervous system disorders2/404/425/4314/40
VomitingGastrointestinal disorders0/404/4211/4311/40
ConstipationGastrointestinal disorders0/405/429/4311/40
HeadacheNervous system disorders3/404/427/436/40
Dry mouthGastrointestinal disorders0/401/426/436/40
SomnolenceNervous system disorders1/403/424/436/40
FatigueGeneral disorders3/406/426/433/40
Decreased appetiteMetabolism and nutrition disorders0/401/425/434/40
DyspnoeaRespiratory, thoracic and mediastinal disorders2/401/422/434/40

Baseline characteristics

The Modified Intent To-Treat Population (mITT) population included all participants who were randomized and had received at least one dose of study drug or placebo.

Age, Continuous
Age, Continuous(years)PlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mgTotal
Mean71.2 ± 7.6669.1 ± 6.9668.5 ± 7.2871.9 ± 6.9570.1 ± 7.29
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mgTotal
Female1113121147
Male29293129118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mgTotal
Hispanic or Latino8109532
Not Hispanic or Latino32323435133
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mgTotal
American Indian or Alaska Native00000
Asian01203
Native Hawaiian or Other Pacific Islander00000
Black or African American00112
White40403839157
More than one race00000
Unknown or Not Reported01203
Hourly 24-Hour Cough Frequency
Hourly 24-Hour Cough Frequency(coughs per hour)PlaceboNAL ER 27 mgNAL ER 54 mgNAL ER 108 mgTotal
Mean29.174 ± 30.504124.571 ± 19.207227.962 ± 29.591131.473 ± 29.254028.265 ± 27.3748
08

Study locations

59 sites
  • Eastern Health-Box Hill Hospital
    Box Hill, 3128, Australia
  • Concord Repatriation General Hospital
    Concord, 2139, Australia
  • Austin Hospital
    Heidelberg, 3084, Australia
  • Respiratory Clinical Trials Pty Ltd
    Kent Town, 5067, Australia
  • TrialsWest Pty Ltd
    Spearwood, 6163, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • CIC Mauricie Inc.
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Dynamic Drug Advancement
    Ajax, L1S 2J5, Canada
  • Centre for Lung Health Clinic
    Vancouver, V5Z 1M9, Canada
  • The Pacific Lung Health Centre - St. Pauls Hospital
    Vancouver, V6Z 1Y6, Canada
  • Hospital Clinico Regional Dr. Guillermo Grant Benavente
    Concepción, 4040324, Chile
  • Centro Respiratorio Integral Ltda
    Quillota, 2260877, Chile
  • Clinica Universidad de los Andes
    Santiago, 7620157, Chile
  • Centro de Investigacion del Maule
    Talca, 3467384, Chile
  • Hospital Carlos Van Buren
    Valparaíso, 2352499, Chile
  • Centro de Investigaciones de Enfermedades Respiratorias e Immunologic Limitada
    Villa Del Mar, 2520598, Chile
  • Universitatsklinik Ruhrlandklinik, Westdeutsches Lungenzentrum
    Essen, 45239, Germany
  • IKF Institut fuer klinische Forschung Frankfurt
    Frankfurt am Main, 60596, Germany
  • Medizinische Hochschule Hannover, Hannover Medical School
    Hanover, 30625, Germany
  • University Hospital of Leipzig
    Leipzig, 04103, Germany
  • IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz
    Mainz, 55128, Germany
  • University Medical Center of Johannes Gutenberg-University Mainz
    Mainz, 55131, Germany
  • Krankenhaus Bethanien
    Solingen, 42699, Germany
  • Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele- Ospedale Gaspare Rodolico
    Catania, 95123, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti Di Foggia
    Foggia, 71122, Italy
  • Azienda Ospedaliera San Gerardo di Monza
    Monza, 20900, Italy
  • Azienda Ospedaliera di Padova
    Padua, 35128, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Rome, 00168, Italy
  • Jeroen Bosch Ziekenhuis
    's-Hertogenbosch, 5223 GZ, Netherlands
  • Martini Ziekenhuis
    Groningen, 9728 NT, Netherlands
  • Erasmus Medisch Centrum 1
    Rotterdam, 3015 GD, Netherlands
  • HMC (Haaglanden Medisch Centrum) Bronovo
    The Hague, 2512 VA, Netherlands
  • Uniwersyteckie Centrum Kliniczne (UCK)
    Gdansk, 80-214, Poland
  • Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego
    Lodz, 90-153, Poland
  • Warminsko Mazurskie Centrum Chorob Pluc w Olsztynie
    Olsztyn, 10-357, Poland
  • Samodzielny Publiczny Wojewodzki Szpital Zespolony w Szczecinie
    Szczecin, 70-891, Poland
  • Clinica Mi Tres Torres Barcelona
    Barcelona, 08017, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Hospital La Milagrosa
    Madrid, 28010, Spain
  • HUMV
    Santander, 39008, Spain
  • Gulhane Askeri Tip Akademisi (GATA) - Gulhane Askeri Tip Fakultesi (Gulhane Military Medical Academy and Medical School)
    Ankara, 06010, Turkey (Türkiye)
  • Akdeniz University Faculty of Medicine
    Antalya, 7070, Turkey (Türkiye)
  • Canakkale Onsekiz Mart Universitesi (COMU) - Tip Fakultesi Hastanesi
    Çanakkale, 17020, Turkey (Türkiye)
  • Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi Egitim ve Arastirma Hastanesi
    Istanbul, 34854, Turkey (Türkiye)
  • Ege University Medical Faculty
    Izmir, 35100, Turkey (Türkiye)
  • Selcuk Universty Medical Faculty
    Konya, 42130, Turkey (Türkiye)
  • Queen Elizabeth Hospital Birmingham - University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2GW, United Kingdom
  • Royal Papworth Hospital
    Cambridge, CB2 0AY, United Kingdom
  • Hull and East Yorkshire - Castle Hill Hospital
    Cottingham, HU16 5JQ, United Kingdom
  • Royal Infirmary Of Edinburgh
    Edinburgh, EH16 4SA, United Kingdom
  • University College London
    London, NW1 2PG, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
  • Altnagelvin Area Hospital
    Londonderry, BT47 6SB, United Kingdom
  • Wythenshawe Hospital
    Manchester, M23 9LT, United Kingdom
  • Norfolk and Norwich University Hospital
    Norwich, NR4 7UY, United Kingdom
  • Nottingham City Hospital
    Nottingham, NG5 1PB, United Kingdom
  • Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
  • Southern Health & Social Care Trust, Craigavon Area Hospital
    Portadown, BT63 5QQ, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Molyneaux PL, Mogulkoc N, Gunen H, Doboszynska A, Kreuter M, Neustifter B, Mathur V, Cassella J; CORAL Study Group. Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough: The CORAL Randomized Clinical Trial. JAMA. 2026 Mar 24;335(12):1050-1059. doi: 10.1001/jama.2025.26179. PubMed 41569557 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2025, 14 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 14 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 27, 2023
StartActual
Feb 6, 2024
Primary completionActual
Apr 24, 2025
CompletionActual
Apr 24, 2025
Results first posted
Jun 26, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05964335
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Feb 6, 2024
Primary completion
Apr 24, 2025
Completion
Apr 24, 2025
Results posted
Jun 26, 2026
Last update
Jun 26, 2026

Study contacts

Chief Development Officer
study director · Trevi Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion